AbCellera Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	35.33	28.83	38.03	485.42	375.2	233.16
Revenue Growth (YoY)	7.17%	-24.17%	-92.17%	29.38%	60.92%	1907.88%
Cost of Revenue	182.81	167.26	175.66	174.32	107.58	56.54
Gross Profit	-147.49	-138.43	-137.63	311.11	267.63	176.62
Selling, General & Admin	85.18	85.49	75.18	66.76	48.76	15.75
Operating Expenses	81.79	144.34	99.57	86.2	63.21	20.59
Operating Income	-229.28	-282.77	-237.21	224.91	204.41	156.03
Interest Expense	-	-	-	-	-	-6.81
Interest & Investment Income	31.08	38.47	42.25	16.08	3.33	0.29
Other Non Operating Income (Expenses)	9.47	11.2	13.1	8.21	11.91	8.32
EBT Excluding Unusual Items	-188.73	-233.1	-181.86	249.2	219.65	157.83
Gain (Loss) on Sale of Investments	0.9	17.4	3.9	-1.7	-0.5	-
Asset Writedown	-32	-32	-	-8.4	-	-
Other Unusual Items	14.9	47.3	3.93	-	-	-
Pretax Income	-204.93	-200.4	-174.03	239.1	219.15	157.83
Income Tax Expense	-33.25	-37.54	-27.63	80.58	65.69	38.92
Net Income	-171.68	-162.86	-146.4	158.52	153.46	118.92
Preferred Dividends & Other Adjustments	-	-	-	-	-	33.82
Net Income to Common	-171.68	-162.86	-146.4	158.52	153.46	85.1
Net Income Growth	-	-	-	3.29%	29.05%	-
Shares Outstanding (Basic)	298	294	289	285	276	159
Shares Outstanding (Diluted)	298	294	289	315	318	263
Shares Change (YoY)	1.57%	1.79%	-8.15%	-1.09%	20.96%	73.88%
EPS (Basic)	-0.58	-0.55	-0.51	0.56	0.56	0.53
EPS (Diluted)	-0.58	-0.55	-0.51	0.50	0.48	0.45
EPS Growth	-	-	-	4.17%	6.21%	-
Free Cash Flow	-153.11	-186.95	-120.82	206.7	186.13	13.02
Free Cash Flow Per Share	-0.51	-0.64	-0.42	0.66	0.58	0.05
Gross Margin	-	-	-	64.09%	71.33%	75.75%
Operating Margin	-649.05%	-980.70%	-623.82%	46.33%	54.48%	66.92%
Profit Margin	-485.99%	-564.83%	-385.00%	32.66%	40.90%	36.50%
Free Cash Flow Margin	-433.43%	-648.40%	-317.75%	42.58%	49.61%	5.58%
EBITDA	-232.66	-223.92	-212.81	244.35	218.88	160.87
EBITDA Margin	-	-	-	50.34%	58.34%	69.00%
D&A For EBITDA	-3.39	58.85	24.4	19.44	14.47	4.84
EBIT	-229.28	-282.77	-237.21	224.91	204.41	156.03
EBIT Margin	-	-	-	46.33%	54.48%	66.92%
Effective Tax Rate	-	-	-	33.70%	29.97%	24.66%
Revenue as Reported	35.33	28.83	38.03	485.42	375.2	233.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.